Ulf‐Henrik Mellqvist

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

Cecilie Blimark, Erik Holmberg, Ulf‐Henrik Mellqvist et al. · Haematologica · 2014 · 537 citations · Full text

Veterinary Medicine, Infectious Diseases, Clinical Epidemiology +13

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 384 citations · Full text

Medicine, Hematology, Oncology +17

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Shaji Kumar, Meletios Α. Dimopoulos, Efstathios Kastritis et al. · Leukemia · 2017 · 354 citations · Full text

Medicine, Immunology, Oncology +17

Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study

Sigurður Y. Kristinsson, Ruth M. Pfeiffer, Magnus Björkholm et al. · Blood · 2010 · 254 citations

Medicine, Hematology, Oncology +12